

Escitalopram (Ciprallex<sup>®</sup>)

(No. 17/02)

Lundbeck Ltd

Summary of Recommendation

*Indication: Major depressive episodes*

8 November 2002

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The recommendation is summarised as follows:

#### **ADVICE**

Not recommended for use in NHS Scotland.

#### **RECOMMENDATIONS**

While escitalopram has been shown to be as effective as citalopram in short-term use, longer-term data are limited and do not address issues such as relapse, remission and withdrawal/rebound phenomena. No clear benefits are demonstrated over the parent product- citalopram.

The license holder has indicated their decision to resubmit in light of additional information now being available.

Professor David H Lawson  
Chairman